Name: Dr. Gul Shahnaz
Designation: Assistant Professor
Department: Pharmacy

Qualifications: PhD (Pharmaceutical Technology) Austria, Post Doc (USA)

Phone: +92-51 9064-4137
Status: On job
Other Weblink:

View Resume

Research Interests Publications Conferences Research Projects

Targeted Nanomedicine for Infectious Diseases

                                                                         Total Impact Factor = 114

1)      Naz K, Shahnaz G, Ahmed N, Qureshi NA, Sarwar HS, Imran M, Khan GM Formulation and In Vitro Characterization of Thiolated Buccoadhesive Film of Fluconazole. AAPS PharmSciTech. (2016); IF (1.95)

2)     Sohail MF,   Javed I,    Hussain SZ,    Sarwar S, Akhtar S,  Nadhman A,  Batool S,  Bukhari NI,     Saleem Z,   Hussain I and   Shahnaz G Folate Grafted Thiolated Chitosan Enveloped Nanoliposomes with Enhanced Oral Bioavailability and Anticancer Activity of Docetaxel , J. Mater. Chem. B, 3, (2016); IF (4.73) 

3)      Khan H, Nadhman A, Azam SS, Anees M, Khan I, Ullah I, Sohail MF, Shahnaz G, Yasinzai M In-vitro Anti-Leishmanial Potential of Peptide Drug Hirudin. Chem Biol Drug Des. (2016) IF (2.802) 

4)      Nadhman A, Khan MI, Nazir S, Khan M, Shahnaz G, Raza A, Shams DF, Annihilation of Leishmania by daylight responsive ZnO nanoparticles: a temporal relationship of reactive oxygen species-induced lipid and protein oxidation Int J Nanomedicine. 31;11:2451-61(2016); IF (4.320) 


5)      Rauf MK, Shaheen U, Asghar F, Badshah A, Nadhman A, Azam S, Ali MI, Shahnaz G, Yasinzai M. Antileishmanial, DNA Interaction, and Docking Studies of Some Ferrocene-Based Heteroleptic Pentavalent Antimonials. Arch Pharm (Weinheim). Jan;349(1):50-6 (2016) IF (1.73) 

6)      Naz K, Fatima QA, Ahmed N, Shahnaz G, Khan GM,Nanoworld: Recent Advances Based on Nanomedicine for Diagnosis and Lung Cancer Therapy J. Colloid Sci. Biotechnol. 4, 1-13(2015)

7)      Javed I,   Hussain,S.Z, Ullah I,     Khan I,  Ateeq M, Shahnaz G Rehman H, Razi MT,  Shah MR and  HussainI, Synthesis, characterization and evaluation of lecithin-based nanocarriers for the enhanced pharmacological and oral pharmacokinetic profile of amphotericin B J. Mater. Chem. B, 3, 8359-8365(2015); IF (4.73) 

8)      Dünnhaupt S, Barthelmes J,  Köllner S, Sakloetsakun D,  Shahnaz G, Düregger A, Bernkop-Schnürch A, Thiolated Nanocarriers for Oral Delivery of Hydrophilic Macromolecular Drugs. Carbohydrate Polymer 6;117:577-84 (2015); IF (4.074)

9)      Nadhman A, Nazir S,  Khan M. I, Arooj S,  Bakhtiar M, Shahnaz G, Yasinzai M,PEGlated Silver Doped Zinc Oxide Nanoparticles as Novel Photosensitizers for Photodynamic Therapy against Leishmania Free Radical Biology & Medicine 77:230-8(2014); IF (5.710) 

10)  Qureshi Q.A. H, Nadhman A,  Sirajuddin M, Shahnaz G, Ali S,  Shah A,  Yasinzai M. M, Organotin (IV) complexes of carboxylate derivative as potential chemotherapeutic agents against Leishmania. Inorganica Chimica Acta ; (2014);IF (2.04) 

11)  Laffleur F, Hintzen F, Shahnaz G, Rahmat D, Leithner K, Bernkop-Schnürch A et al.,  Development and in vitro evaluation of slippery nanoparticles for enhanced diffusion through native mucus. Nanomedicine (Lond).  9 (3), 387-396(2013) ; IF (5.824) 

12)  Yasinzai M, Khan M, Nadhman A, Shahnaz G.Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. Future Med Chem5(15):1877-88 (2013) ; IF (4) 

13)   Millotti G, Vetter A, Leithner K,  Sarti F, Shahnaz G, Augustijns P,  Bernkop-Schnürch A, Development of thiolated poly (acrylic acid) microparticles for the nasal administration of exenatide. Drug Dev Ind Pharm. (2013) ; IF (2.006) 

14)  Laffleur F, Shahnaz G, Islambulchilar Z, Bernkop-Schnürch A.Design and in vitro evaluation of a novel polymeric excipient for buccal applications. Future Med Chem5(5):511-22 (2013) ; IF (4) 

15)  Shahnaz G, Kremser C, Reinisch A, Vetter A et al., Efficient MRI labeling of endothelial progenitor cells: Design of thiolated surface stabilized superparamagnetic iron oxide nanoparticles. Eur J Pharm Biopharm. 85(3):346-55 (2013); IF (4.245) 

16)  Rahmat D, Müller C, Barthelmes J, Shahnaz G, Martien R, Bernkop-Schnürch A. Thiolated hydroxyethyl cellulose: Design and in vitro evaluation of mucoadhesive and permeation enhancing nanoparticles. Eur J Pharm Biopharm. 5(1): 1-6 (2012); IF (3.826) 

17)  Laffleur F, Hintzen F, Rahmat D, Shahnaz G, Millotti G, Bernkop-Schnürch A.. Enzymatic degradation of thiolated chitosan. Drug Dev Ind Pharm. ; IF (1.54) 

18)  Hintzen F, Laffleur F, Sarti F, Shahnaz G, Bernkop-Schnürch A.. Thiomers: influence of molar mass on in situ gelling properties. Int J Pharm. 436(1-2):120-6 (2012) ; IF (3.458) 

19)  Rahmat D, Müller C, Shahnaz G, Leithner K, Laffleur F, Khan MI, Martien R, Schnürch AB. Douroumis, M.A. HEC-cysteamine particles: influence of particle size, zeta potential, morphology and sulfhydryl groups on permeation enhancing properties.. Drug Dev Ind Pharm. ; IF (1.54) 

20)  Rahmat D, Khan MI, Shahnaz G, Sakloetsakun D, Perera G, Bernkop-Schnürch A. Synergistic effects of conjugating cell penetrating peptides and thiomers on non-viral transfection efficiency. Biomaterials 33(7):2321-6 (2012) ; IF (7.604)

21)  Iqbal J, Shahnaz G, Dünnhaupt S, Müller C, Hintzen F, Bernkop-Schnürch A. Preactivated thiomers as mucoadhesive polymers for drug delivery. Biomaterials 33(5):1528-35 (2012) ; IF (7.604)

22)  Rahmat D, Sakloetsakun D, Shahnaz G, Sarti F, Laffleur F, Schnürch AB. HEC-cysteamine conjugates: influence of degree of thiolation on efflux pump inhibitory and permeation enhancing properties. Int J Pharm. 25(4) 751-756 (2012) ; IF (3.458) 

23)  Iqbal J, Shahnaz G, Perera G, Hintzen F, Sarti F, Bernkop-Schnürch A. Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. Eur J Pharm Biopharm. 80(1):95-102. (2012) IF (3.826) 

24)  Sarti F, Iqbal J, Müller C, Shahnaz G, Rahmat D, Bernkop-Schnürch A.  Poly(acrylic acid)-cysteine for oral vitamin B12 delivery.. Anal Biochem. 420(1):13-9 (2012) IF (2.582) 

25)  Shahnaz G, Vetter A, Barthelmes J, Rahmat D, et. al., Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. Int J Pharm. 428(1-2):164-70 (2012) IF (3.458) 

26)  Shahnaz G, Iqbal J, Rahmat D, Perera G, Laffleur F, Rossi D, Bernkop-Schnürch A, Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life J Control Release. 157(3):375-82 (2012) IF (7.633) 

27)  Shahnaz G,  Hartl M, Barthelmes J, Leithner K, et. al., Uptake of phenothiazines by the harvested chylomicrons ex vivo model: influence of self-nanoemulsifying formulation design. Eur J Pharm Biopharm.79(1):171-180. (2011) IF (4.269)

28)  Rahmat D,  Sakloetsakun D, Shahnaz G, Perera G, Kaindl R,  Bernkop-Schnürch A, Design and synthesis of a novel cationic thiolated polymer. Int J Pharm.  411(1-2):10-17 (2011) (3.35) 

29)  Shahnaz G, Perera G, Sakloetsakun D, Rahmat D, Bernkop-Schnürch A. Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran-cysteine conjugate.   J Control Release. 44(1):33-38 (2010); IF (7.164) 

1)       Conference on "5th Annual Meeting Center for Molecular Biosciences (CMBI)" 26th – 27th 2008, Igls, Tyrol, Austria

2)       Conference on "Life Science Meeting" 18th -19th September 2009, Igls, Tyrol, Austria

3)       Conference on "EuroNanoMedicine" 28th – 30th September 2009, Bled, Slovenia

4)       Conference on "6th Meeting of the Doctoral students from Innsbrucks Medical University and of the life sciences disciplines of the Leopold-Franzens Universitat Innsbruck" 24th November, 2010, Innsbruck, Austria

5)       Conference on "2nd Annual Meeting for Life Sciences" 24th -25th 2010 September, Igls, Tyrol, Austria

6)       Conference on "Joint Meeting of the Austrian and German Pharmaceutical Societies" 20th -23rd September, 2011, Innsbruck, Austria

7)       Conference on "3rd International Conference on Drug Discovery and Therapy (ICDDT)" 7th -10th February 2011, Dubai, UAE

8)       Conference on "7th Meeting of the Doctoral students from Innsbrucks Medical University and of the life sciences disciplines of the Leopold-Franzens Universitat Innsbruck" 11th November 2011, Innsbruck,  Austria

9)       17th International Pharmacy Conference & Exhibition, 19th – 21th  September  2012, Islamabad, Pakistan

10)   Conference on "9th Biennial International Conference of Pakistan Society for Microbiology" Karachi 28th -31th January, 2013,Karachi, Pakistan

11)   Engaging Private Pharmacies in TB Care & Control - Training Workshop,  15th  July, 2013, Network of Development Professionals, Islamabad, Pakistan

12)   1st International conference on Drug Development- Natural & Synthetic, 25th  - 27th  August, 2013, Comsats-Abbottabad, Pakistan

13) International Symposium on Nanomaterials. "Nanomaterials – Potential Applications & Challenges, 31th  October, 2013, Lahore University of Management Sciences, Lahore, Pakistan

14)   18th International Pharmacy Conference & Exhibition, 31th October 2nd November, 2013, Pakistan Pharmacist Association, Lahore, Pakistan.

15)   Promoting Research and Publication in Pharmaceutical Policy and Practice 20th December 2013 Health Services Academy, Islamabad, Pakistan

16)   Recent Advances in Nanotechnology,   January 6, 2014, PINSAT, Preston University Islamabad

17)   For Women in Science Week, 16th -20th March, 2014, UNESCO head office, Paris, France

18)   Good Governance for Medicines (GGM),21th – 23th April,  World Health Organization Lahore, Pakistan

19)   Pharmaceutical Sector Assessment Survey - Level II, 15th -17th September 2014,World Health Organization,  Islamabad, Pakistan

20)   2nd International Workshop Pharmacy Practice/Clinical Pharmacy,15th -19th December 2014,Quaid-i-Azam ,  Islamabad, Pakistan

21)   Sixth Structural Biology & Molecular Biophysics Workshop,9th July 2015, University of Nebraska Medical Center(UNMC),  Durham Research Center ,Omaha, USA

22)   Seminar on Adventures in the Small World: A Novel Approach to Understanding Intracellular Events During HIV-1 Infection of the CNS, 17th July 2015, University of Nebraska Medical Center(UNMC), Eppley Science Hall ,Omaha, USA

23)   Seminar on Hybridtides and the Artisan Biology platform - Towards oral delivery and novel therapeutic mechanisms 28th July 2015, University of Nebraska Medical Center(UNMC),  Durham Research Center ,Omaha, USA

24)   International Nanomedicines Symposium on Nanotheranostics, 26th November 2015,NORI, Islamabad

25)   International Symposium, Nanomedicines: Development, Testing and Application Possibilities, 1st March 2016, NORI, Islamabad

26)   ISESCO Women in Science Conference on Contributions of Pakistani Women in Scientific and Social Development, 8th March 2016,QAU, Islamabad

1.       "Comparative bioavailability & pharmacokinetic characterization of phenothiazines by using self-nanoemulsifying drug delivery system" (0.5 million) By: Higher Education Commission, Pakistan ( Completed; 2012-2013) P.I (Dr. Gul Shahnaz) Co-PI ( Dr. Gul Majid Khan)

2.       Nanoparticles based on Thiolated Polymeric Excipients: Promising Tool for Amphotericin B Drug Delivery in Leishmaniasis Therapy” (34,000 Pk/Rs.)  By: URF,Quaid-i-Azam University ( Completed; 2012) P.I (Dr. Gul Shahnaz)

3.       Mucoadhesive In Situ Gel based on Thiomeric Excipients: Novel Strategy for Leishmaniasis Drug Delivery   (24,000 Pk/Rs)   By: URF,Quaid-i-Azam University( Completed; 2013)  P.I (Dr. Gul Shahnaz)  

4.        Monocyte-macrophage as targeted drug depots for long acting anti-microbial medicines (20,000 US dollars)  By:  L’Oréal-UNESCO (Completed; 2014-2015) P.I (Dr. Gul Shahnaz)

5.       Synthesis and characterization of Polyethyleneimine-g-Poly(caprolactone-co-lactic acid) for the control release of drugs (50,000 Pk/Rs)  By: URF,Quaid-i-Azam University ( Completed; 2014) P.I (Dr. Gul Shahnaz)

6.       Synthesis and characterization of Polyethyleneimine-g-Chitosan nanoparticles for drug delivery (100,000 Pk/Rs)  By: URF,Quaid-i-Azam University ( Completed; 2015) P.I (Dr. Gul Shahnaz)

7.       Evaluation of mannose-anchored thiolated nanocarriers for improved oral bioavailability of amphotericin B against leishmaniasis therapy (20,000 US dollars)   By:  L’Oréal-UNESCO (Approved for 2015-2016) P.I (Dr. Gul Shahnaz)

8.       Development and evaluation of mannose-anchored thiolated nanocarriers for leishmaniasis therapy By:   COMSTECH-TWAS (4,400 US dollars) (Approved for 2016-2017) P.I (Dr. Gul Shahnaz)

9.       Synthesis and characterization of a disulfide cross-linked multifunctional in situ gelling cargo for oral peptide drug delivery  By:   Pakistan Academy of Sciences (0.927 Millions)  (Approved for 2016-2018) P.I (Dr. Gul Shahnaz)

10.    Development of Thiolated Polymer Coated Gel: Promising Platform for Controlled and Targeted Drug Delivery in Leishmaniasis  By:   Higher Education Commission, Pakistan (14.5 Millions)  (Approved for 2016-2019) Co-P.I (Dr. Gul Shahnaz), P.I (Dr. Gul Majid Khan)

11.   Synthesis and Evaluation of Doped Phototoxic Nanoparticles based Topical Skin-care Cream as a Novel, Cheap Substitute to Current Treatment for Leishmania Infection  By:   Pakistan Science Foundation (7 Millions)  (Approved for 2015-2018) Co-P.I (Dr. Gul Shahnaz), P.I (Prof. Dr. Masoom Yasinzai)

Quaid-i-Azam University Islamabad, 45320, Pakistan.
Tel: +92-51 9064 0000,